Search

Displaying results 2411 - 2420 of 7600 in total
  1. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis).

  2. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    Currently under investigation for use in psychotic depression (phase 3 trials). … Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua.

    Categories: Hormonal Contraceptives for Systemic Use
  3. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It is being developed by Alizyme of the UK. … Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C).

  4. Drug

    Spiramycin

    go.drugbank.com/drugs/DB06145
    ApprovedInvestigationalWithdrawn

    Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii an...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    [L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns.

  6. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.

  8. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    >A</sub>R and 0.8 nM for AT<sub>1</sub>R). … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub

  9. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

  10. Drug

    Mebeverine

    go.drugbank.com/drugs/DB12554
    ApprovedInvestigationalWithdrawn

    Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

    Categories: Drugs for Functional Gastrointestinal Disorders